JP2010530220A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530220A5 JP2010530220A5 JP2010510887A JP2010510887A JP2010530220A5 JP 2010530220 A5 JP2010530220 A5 JP 2010530220A5 JP 2010510887 A JP2010510887 A JP 2010510887A JP 2010510887 A JP2010510887 A JP 2010510887A JP 2010530220 A5 JP2010530220 A5 JP 2010530220A5
- Authority
- JP
- Japan
- Prior art keywords
- variable domain
- antagonist
- sequence
- dom4
- interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000010932 Interleukin-1 receptor type 1 Human genes 0.000 claims 21
- 108050001109 Interleukin-1 receptor type 1 Proteins 0.000 claims 21
- 239000005557 antagonist Substances 0.000 claims 16
- 108060003951 Immunoglobulin Proteins 0.000 claims 14
- 102000018358 immunoglobulin Human genes 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 3
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 3
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 3
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 3
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 3
- 102000000589 Interleukin-1 Human genes 0.000 claims 3
- 108010002352 Interleukin-1 Proteins 0.000 claims 3
- 108091005804 Peptidases Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000016387 Pancreatic elastase Human genes 0.000 claims 1
- 108010067372 Pancreatic elastase Proteins 0.000 claims 1
- 108010019160 Pancreatin Proteins 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 229940100601 interleukin-6 Drugs 0.000 claims 1
- 229940096397 interleukin-8 Drugs 0.000 claims 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 229940055695 pancreatin Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
- 238000013389 whole blood assay Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93363207P | 2007-06-06 | 2007-06-06 | |
| US60/933,632 | 2007-06-06 | ||
| GBGB0724331.4A GB0724331D0 (en) | 2007-12-13 | 2007-12-13 | Compositions for pulmonary delivery |
| GB0724331.4 | 2007-12-13 | ||
| PCT/GB2008/050406 WO2008149149A2 (en) | 2007-06-06 | 2008-06-04 | Polypeptides, antibody variable domains and antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010530220A JP2010530220A (ja) | 2010-09-09 |
| JP2010530220A5 true JP2010530220A5 (enExample) | 2011-07-14 |
| JP5444215B2 JP5444215B2 (ja) | 2014-03-19 |
Family
ID=39791116
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010510887A Active JP5444215B2 (ja) | 2007-06-06 | 2008-06-04 | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
| JP2010510886A Expired - Fee Related JP5325211B2 (ja) | 2007-06-06 | 2008-06-04 | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
| JP2010510888A Pending JP2010530364A (ja) | 2007-06-06 | 2008-06-04 | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010510886A Expired - Fee Related JP5325211B2 (ja) | 2007-06-06 | 2008-06-04 | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
| JP2010510888A Pending JP2010530364A (ja) | 2007-06-06 | 2008-06-04 | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US8398979B2 (enExample) |
| EP (5) | EP2746291B1 (enExample) |
| JP (3) | JP5444215B2 (enExample) |
| KR (4) | KR20100018040A (enExample) |
| CN (4) | CN101883788A (enExample) |
| AR (3) | AR066848A1 (enExample) |
| AU (4) | AU2008259590A1 (enExample) |
| BR (3) | BRPI0812795C1 (enExample) |
| CA (6) | CA2683791A1 (enExample) |
| CL (3) | CL2008001673A1 (enExample) |
| CO (2) | CO6251321A2 (enExample) |
| CR (2) | CR11194A (enExample) |
| CY (1) | CY1116762T1 (enExample) |
| DK (1) | DK2162467T3 (enExample) |
| DO (1) | DOP2009000268A (enExample) |
| EA (5) | EA200901494A1 (enExample) |
| ES (1) | ES2546943T3 (enExample) |
| HR (1) | HRP20151024T1 (enExample) |
| HU (1) | HUE025899T2 (enExample) |
| IL (2) | IL201398A0 (enExample) |
| MA (2) | MA31403B1 (enExample) |
| MX (4) | MX2009013137A (enExample) |
| NZ (1) | NZ581372A (enExample) |
| PE (3) | PE20090763A1 (enExample) |
| PL (1) | PL2162467T3 (enExample) |
| PT (1) | PT2162467E (enExample) |
| SG (2) | SG182151A1 (enExample) |
| SI (1) | SI2162467T1 (enExample) |
| TW (6) | TW200911832A (enExample) |
| WO (3) | WO2008149149A2 (enExample) |
| ZA (1) | ZA200908470B (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| DE102005023617A1 (de) | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
| AU2008259590A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Methods for selecting protease resistant polypeptides |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| NZ580530A (en) * | 2007-06-06 | 2012-04-27 | Domantis Ltd | Anti vegf polypeptides, antibody variable domains and antagonists |
| TW200938222A (en) * | 2007-12-13 | 2009-09-16 | Glaxo Group Ltd | Compositions for pulmonary delivery |
| CN102089325A (zh) | 2008-04-17 | 2011-06-08 | 埃博灵克斯股份有限公司 | 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽 |
| HRP20241467T1 (hr) | 2008-06-25 | 2025-01-03 | Novartis Ag | Stabilna i topljiva protutijela koja inhibiraju vegf |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| KR20110091777A (ko) * | 2008-11-26 | 2011-08-12 | 글락소 그룹 리미티드 | 폴리펩티드, 항체 가변 도메인 및 길항제 |
| WO2010081787A1 (en) | 2009-01-14 | 2010-07-22 | Domantis Limited | IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS |
| MX2011008752A (es) | 2009-02-19 | 2011-09-06 | Glaxo Group Ltd | Variantes de union a anti-albumina de suero mejoradas. |
| ES2655071T3 (es) | 2009-02-19 | 2018-02-16 | Glaxo Group Limited | Variantes de unión de anti-albúmina de suero mejoradas |
| EA022925B1 (ru) * | 2009-02-19 | 2016-03-31 | Глаксо Груп Лимитед | Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1 |
| US20110305692A1 (en) | 2009-02-24 | 2011-12-15 | Glaxo Group Limited | Antigen-binding contructs |
| EP2454285A2 (en) | 2009-07-16 | 2012-05-23 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
| WO2011006914A2 (en) | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Antagonists, uses & methods for partially inhibiting tnfr1 |
| AU2010306718A1 (en) * | 2009-10-14 | 2012-05-24 | Aileron Therapeutics, Inc. | Improved peptidomimetic macrocycles |
| TW201125877A (en) | 2009-10-27 | 2011-08-01 | Glaxo Group Ltd | Stable anti-TNFR1 polypeptides, antibody variable domains & and antagonists |
| CN102781959A (zh) | 2010-02-05 | 2012-11-14 | 埃博灵克斯股份有限公司 | 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽 |
| EA201291009A1 (ru) | 2010-05-20 | 2013-05-30 | Глаксо Груп Лимитед | Улучшенные связывающие варианты против сывороточного альбумина |
| US9012609B2 (en) * | 2010-08-13 | 2015-04-21 | Glaxosmithkline Intellectual Property Development Limited | Anti-serum albumin binding variants |
| SG188204A1 (en) | 2010-08-20 | 2013-04-30 | Glaxo Group Ltd | Improved anti-serum albumin binding variants |
| CN103249742B (zh) * | 2010-09-16 | 2017-04-12 | 巴利奥医药股份公司 | 抗人肿瘤坏死因子1型受体抗体 |
| WO2012072731A2 (en) | 2010-12-01 | 2012-06-07 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
| WO2012104227A1 (en) | 2011-02-02 | 2012-08-09 | Glaxo Group Limited | Novel antigen binding proteins |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| SG10201601621PA (en) | 2011-06-28 | 2016-04-28 | Inhibrx Llc | Serpin fusion polypeptides and methods of use thereof |
| JP5987057B2 (ja) * | 2011-07-27 | 2016-09-06 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｆｃドメインと融合した抗ｖｅｇｆ単一可変ドメイン |
| PE20141522A1 (es) * | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| GB2497138A (en) * | 2011-12-02 | 2013-06-05 | Randox Lab Ltd | Biomarkers for stroke and stroke subtype diagnosis. |
| LT3495387T (lt) | 2012-07-13 | 2021-11-25 | Roche Glycart Ag | Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| EP2951192A1 (en) * | 2013-01-31 | 2015-12-09 | Glaxo Group Limited | Method of producing a protein |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| GB201617622D0 (en) * | 2016-10-18 | 2016-11-30 | VIB VZW and Universiteit Gent | Means and methods to treat inflammation |
| RU2625010C1 (ru) * | 2016-11-10 | 2017-07-11 | Илья Петрович Приколаб | Экспрессионный плазмидный вектор для экспрессии активной формы TNFR1-Fc и способ получения рекомбинантного белка |
| MX2019005756A (es) | 2016-11-28 | 2019-08-14 | Chugai Pharmaceutical Co Ltd | Dominio de union al antigeno y polipeptido que incluye seccion de transporte. |
| TW202235438A (zh) | 2016-11-28 | 2022-09-16 | 日商中外製藥股份有限公司 | 能夠調節配體結合活性的配體結合分子 |
| UY37651A (es) * | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | Polipéptido de unión al il-1r-i |
| CA3079096A1 (en) * | 2017-11-01 | 2019-05-09 | Allogene Therapeutics, Inc. | Modified caspase-9 polypeptides and methods of use thereof |
| EP3719035A4 (en) | 2017-11-28 | 2021-09-01 | Chugai Seiyaku Kabushiki Kaisha | POLYPEPTIDE WITH ANTIGEN-BINDING AREA AND CARRYING SECTION |
| TWI880235B (zh) | 2017-11-28 | 2025-04-11 | 日商中外製藥股份有限公司 | 可調整配體結合活性的配體結合分子 |
| WO2019154776A1 (en) | 2018-02-06 | 2019-08-15 | F. Hoffmann-La Roche Ag | Treatment of ophthalmologic diseases |
| US12071476B2 (en) | 2018-03-02 | 2024-08-27 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
| JP7414736B2 (ja) | 2018-05-30 | 2024-01-16 | 中外製薬株式会社 | アグリカン結合ドメインおよび運搬部分を含むポリペプチド |
| JP7428661B2 (ja) * | 2018-05-30 | 2024-02-06 | 中外製薬株式会社 | Ｉｌ－１ｒ１結合ドメインおよび運搬部分を含むポリペプチド |
| PL3623798T3 (pl) * | 2018-09-13 | 2022-03-28 | Euroimmun Medizinische Labordiagnostika Ag | Sposób i urządzenie do wykrywania i przedstawiania obrazu immunofluorescencyjnego próbki biologicznej |
| CN112955240B (zh) * | 2018-10-25 | 2022-09-16 | 豪夫迈·罗氏有限公司 | 抗体FcRn结合的修饰 |
| SG11202103064YA (en) | 2018-10-29 | 2021-05-28 | Hoffmann La Roche | Antibody formulation |
| SG11202105476XA (en) | 2018-12-06 | 2021-06-29 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| CN111454366B (zh) * | 2019-01-21 | 2023-06-16 | 中国科学院深圳先进技术研究院 | 一种融合蛋白及其应用 |
| US12265083B2 (en) * | 2019-01-31 | 2025-04-01 | Sekisui Medical Co., Ltd. | Immunoassay method for free AIM in biological sample, and assay kit |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| JP7473398B2 (ja) * | 2020-05-28 | 2024-04-23 | シスメックス株式会社 | キャリブレータ、複合体、及びＩｇＡ凝集体を測定する方法 |
| JP2023541816A (ja) | 2020-08-27 | 2023-10-04 | イノージ・セラピューティクス・コーポレイション | 自己免疫性疾患および癌を治療するための方法および組成物 |
| WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
| CN115181751A (zh) * | 2021-04-02 | 2022-10-14 | 苏州博腾生物制药有限公司 | 靶向白蛋白的嵌合抗原受体及其使用方法 |
| CN114657162B (zh) * | 2022-03-04 | 2023-06-16 | 华南理工大学 | 一种具有血管内皮细胞保护功能的抗氧化五肽及其应用 |
| CN115112704B (zh) * | 2022-06-21 | 2025-07-15 | 中特检验集团有限公司 | 一种光热发电有机热载体热稳定性检测方法 |
| US12098400B2 (en) | 2022-07-08 | 2024-09-24 | Novo Nordisk A/S | Highly potent ISVD compounds capable of substituting for FVIII(A) |
| WO2025049818A1 (en) | 2023-08-29 | 2025-03-06 | Enosi Therapeutics Corporation | Tnfr1 antagonists lacking agonist activity and uses thereof |
| CN119909772B (zh) * | 2025-04-01 | 2025-06-20 | 安徽一帆新材料科技有限公司 | 用于净水的再生阴树脂及其制备方法 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| EP0768377A1 (en) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
| ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2155822T3 (es) | 1990-12-06 | 2001-06-01 | Affymetrix Inc | Compuestos y su utilizacion en una estrategia de sintesis binaria. |
| PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
| ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| HU230048B1 (hu) * | 1996-02-09 | 2015-06-29 | Abbvie Biotechnology Ltd | Humán TNFalfa-kötő antitestek alkalmazása |
| ES2283936T3 (es) | 1997-07-07 | 2007-11-01 | Medical Research Council | Procedimiento de clasificacion in vitro. |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| DK1078051T3 (da) | 1998-05-13 | 2008-04-07 | Domantis Ltd | Fagvisningsselektionssystem til selektion af korrekt foldede proteiner |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| AU3040101A (en) | 2000-02-03 | 2001-08-14 | Domantis Limited | Combinatorial protein domains |
| EP1263788A2 (en) | 2000-02-11 | 2002-12-11 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
| US7265210B2 (en) * | 2000-09-15 | 2007-09-04 | Genentech, Inc. | Anti-PRO9821 antibodies |
| AU1994402A (en) | 2000-11-28 | 2002-06-11 | Mediummune Inc | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
| US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| AU2002319402B2 (en) | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
| GB0118689D0 (en) * | 2001-08-01 | 2001-09-19 | Psimedica Ltd | Pharmaceutical formulation |
| WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| US7696320B2 (en) * | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| EP1600459A3 (en) | 2002-06-28 | 2005-12-07 | Domantis Limited | Ligand |
| CN104178491B (zh) | 2002-09-06 | 2018-07-03 | 安姆根有限公司 | 治疗性人抗-il-1r1单克隆抗体 |
| ES2614274T3 (es) | 2002-09-06 | 2017-05-30 | Alexion Pharmaceuticals, Inc. | Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5 |
| EP2284192A3 (en) | 2002-11-08 | 2011-07-20 | Ablynx N.V. | Camelidae antibodies for sublingual administration |
| JP2006523090A (ja) * | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体 |
| GB0230203D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| SI1639011T1 (sl) * | 2003-06-30 | 2009-04-30 | Domantis Ltd | Pegilirana protitelesa z enojno domeno (dAb) |
| JP5010923B2 (ja) | 2004-02-09 | 2012-08-29 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | アルブミン融合蛋白質 |
| PL1737962T3 (pl) | 2004-03-24 | 2011-02-28 | Domantis Ltd | Uniwersalny lider GAS1 |
| EP1802334B1 (en) * | 2004-10-21 | 2012-08-29 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
| CA2588892A1 (en) * | 2004-12-02 | 2006-06-08 | Dormantis Limited | Anti-il-1r1 single domain antibodies and therapeutic uses |
| GB0521621D0 (en) * | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| CN101454344A (zh) * | 2005-12-01 | 2009-06-10 | 杜门蒂斯有限公司 | 与白细胞介素-1受体1型结合的非竞争性域抗体形式 |
| KR20080077237A (ko) | 2005-12-01 | 2008-08-21 | 도만티스 리미티드 | 인터루킨 1 수용체 타입 1에 결합하는 경쟁적 도메인 항체포맷 |
| US8940683B2 (en) | 2006-08-10 | 2015-01-27 | Roy C. Levitt | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
| US20100129354A1 (en) * | 2006-10-27 | 2010-05-27 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
| AU2008259590A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Methods for selecting protease resistant polypeptides |
| NZ580530A (en) | 2007-06-06 | 2012-04-27 | Domantis Ltd | Anti vegf polypeptides, antibody variable domains and antagonists |
-
2008
- 2008-06-03 AU AU2008259590A patent/AU2008259590A1/en not_active Abandoned
- 2008-06-03 MX MX2009013137A patent/MX2009013137A/es not_active Application Discontinuation
- 2008-06-03 EA EA200901494A patent/EA200901494A1/ru unknown
- 2008-06-03 CA CA002683791A patent/CA2683791A1/en not_active Abandoned
- 2008-06-03 CA CA002688434A patent/CA2688434A1/en not_active Abandoned
- 2008-06-03 CA CA002688433A patent/CA2688433A1/en not_active Abandoned
- 2008-06-03 KR KR1020107000188A patent/KR20100018040A/ko not_active Withdrawn
- 2008-06-04 EP EP13184211.4A patent/EP2746291B1/en active Active
- 2008-06-04 BR BRPI0812795A patent/BRPI0812795C1/pt not_active IP Right Cessation
- 2008-06-04 AR ARP080102363A patent/AR066848A1/es not_active Application Discontinuation
- 2008-06-04 CA CA2688447A patent/CA2688447C/en active Active
- 2008-06-04 EP EP08750801A patent/EP2164867A2/en not_active Withdrawn
- 2008-06-04 EP EP13184209.8A patent/EP2746290B1/en active Active
- 2008-06-04 CN CN2008801020043A patent/CN101883788A/zh active Pending
- 2008-06-04 EA EA200901300A patent/EA200901300A1/ru unknown
- 2008-06-04 EA EA200901491A patent/EA018129B1/ru not_active IP Right Cessation
- 2008-06-04 BR BRPI0812268A patent/BRPI0812268A2/pt not_active IP Right Cessation
- 2008-06-04 HR HRP20151024TT patent/HRP20151024T1/hr unknown
- 2008-06-04 CN CN201410440384.9A patent/CN104311663B/zh not_active Expired - Fee Related
- 2008-06-04 NZ NZ581372A patent/NZ581372A/en not_active IP Right Cessation
- 2008-06-04 BR BRPI0813899A patent/BRPI0813899A2/pt not_active IP Right Cessation
- 2008-06-04 MX MX2009013211A patent/MX2009013211A/es active IP Right Grant
- 2008-06-04 US US12/663,502 patent/US8398979B2/en not_active Expired - Fee Related
- 2008-06-04 HU HUE08750800A patent/HUE025899T2/en unknown
- 2008-06-04 AR ARP080102365A patent/AR066850A1/es not_active Application Discontinuation
- 2008-06-04 KR KR1020107000213A patent/KR20100041746A/ko not_active Withdrawn
- 2008-06-04 DK DK08750800.8T patent/DK2162467T3/en active
- 2008-06-04 US US12/663,506 patent/US20100247515A1/en not_active Abandoned
- 2008-06-04 AR ARP080102362A patent/AR066847A1/es unknown
- 2008-06-04 ES ES08750800.8T patent/ES2546943T3/es active Active
- 2008-06-04 CN CN200880102207.2A patent/CN101778865B/zh not_active Expired - Fee Related
- 2008-06-04 KR KR1020107000223A patent/KR20100040841A/ko not_active Withdrawn
- 2008-06-04 JP JP2010510887A patent/JP5444215B2/ja active Active
- 2008-06-04 PL PL08750800T patent/PL2162467T3/pl unknown
- 2008-06-04 PE PE2008000943A patent/PE20090763A1/es not_active Application Discontinuation
- 2008-06-04 EA EA200901495A patent/EA018723B1/ru not_active IP Right Cessation
- 2008-06-04 MX MX2009013138A patent/MX2009013138A/es active IP Right Grant
- 2008-06-04 PT PT87508008T patent/PT2162467E/pt unknown
- 2008-06-04 JP JP2010510886A patent/JP5325211B2/ja not_active Expired - Fee Related
- 2008-06-04 SG SG2012040275A patent/SG182151A1/en unknown
- 2008-06-04 CN CN200880019060A patent/CN101802004A/zh active Pending
- 2008-06-04 JP JP2010510888A patent/JP2010530364A/ja active Pending
- 2008-06-04 WO PCT/GB2008/050406 patent/WO2008149149A2/en not_active Ceased
- 2008-06-04 AU AU2008259514A patent/AU2008259514B2/en not_active Ceased
- 2008-06-04 MX MX2009012967A patent/MX2009012967A/es not_active Application Discontinuation
- 2008-06-04 SI SI200831508T patent/SI2162467T1/sl unknown
- 2008-06-04 AU AU2008259515A patent/AU2008259515A1/en not_active Abandoned
- 2008-06-04 CA CA002683823A patent/CA2683823A1/en not_active Abandoned
- 2008-06-04 SG SG2012039541A patent/SG182141A1/en unknown
- 2008-06-04 PE PE2008000944A patent/PE20090323A1/es not_active Application Discontinuation
- 2008-06-04 WO PCT/GB2008/050407 patent/WO2008149150A2/en not_active Ceased
- 2008-06-04 PE PE2008000940A patent/PE20090322A1/es not_active Application Discontinuation
- 2008-06-04 AU AU2008259516A patent/AU2008259516A1/en not_active Abandoned
- 2008-06-04 EP EP08750800.8A patent/EP2162467B1/en active Active
- 2008-06-04 WO PCT/GB2008/050405 patent/WO2008149148A2/en not_active Ceased
- 2008-06-04 KR KR1020107000212A patent/KR101604274B1/ko not_active Expired - Fee Related
- 2008-06-04 EP EP08750802A patent/EP2162468A2/en not_active Withdrawn
- 2008-06-04 CA CA002688456A patent/CA2688456A1/en not_active Abandoned
- 2008-06-06 TW TW097121295A patent/TW200911832A/zh unknown
- 2008-06-06 TW TW097121268A patent/TW200911831A/zh unknown
- 2008-06-06 CL CL2008001673A patent/CL2008001673A1/es unknown
- 2008-06-06 TW TW097121296A patent/TW200902551A/zh unknown
- 2008-06-06 TW TW097121280A patent/TW200907128A/zh unknown
- 2008-06-06 TW TW097121301A patent/TW200918088A/zh unknown
- 2008-06-06 TW TW097121265A patent/TW200911834A/zh unknown
- 2008-06-06 CL CL2008001676A patent/CL2008001676A1/es unknown
- 2008-06-06 CL CL2008001674A patent/CL2008001674A1/es unknown
- 2008-11-26 US US12/323,632 patent/US20090148437A1/en not_active Abandoned
-
2009
- 2009-10-11 IL IL201398A patent/IL201398A0/en unknown
- 2009-11-04 US US13/130,656 patent/US20110256122A1/en not_active Abandoned
- 2009-11-04 EA EA201100546A patent/EA201100546A1/ru unknown
- 2009-11-18 IL IL202204A patent/IL202204A0/en unknown
- 2009-11-27 DO DO2009000268A patent/DOP2009000268A/es unknown
- 2009-11-30 ZA ZA2009/08470A patent/ZA200908470B/en unknown
- 2009-11-30 MA MA32388A patent/MA31403B1/fr unknown
- 2009-12-14 CO CO09142781A patent/CO6251321A2/es not_active Application Discontinuation
- 2009-12-14 CO CO09142782A patent/CO6251322A2/es not_active Application Discontinuation
-
2010
- 2010-01-04 MA MA32475A patent/MA31668B1/fr unknown
- 2010-01-06 CR CR11194A patent/CR11194A/es not_active Application Discontinuation
- 2010-01-06 CR CR11195A patent/CR11195A/es unknown
-
2011
- 2011-11-17 US US13/299,030 patent/US20120134982A1/en not_active Abandoned
-
2015
- 2015-10-06 CY CY20151100886T patent/CY1116762T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021244089A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 | |
| TWI539963B (zh) | 抗－人類呼吸道融合性病毒（ｒｓｖ）抗體及其使用方法 | |
| CN107109456B (zh) | 靶向IL-23A和TNF-α的化合物及其用途 | |
| CN108178800B (zh) | 具有降低的与抗药物抗体结合的经修饰的单可变结构域抗体 | |
| JP2023504914A5 (enExample) | ||
| JP2017527272A5 (enExample) | ||
| CN101611056A (zh) | 能够结合于血清蛋白的肽 | |
| WO2020173460A1 (zh) | 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用 | |
| RS55609B1 (sr) | Fc fuzioni proteini koji sadrže nove linkere ili aranžmane | |
| JP2012517818A5 (enExample) | ||
| JP2009517069A5 (enExample) | ||
| CN105283467A (zh) | 抗tnf-抗il-17双特异性抗体 | |
| JP2021533204A5 (enExample) | ||
| CN114736291B (zh) | 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途 | |
| WO2023019723A1 (zh) | 单克隆抗体32c7及其制备方法和用途 | |
| WO2021205184A1 (en) | Polypeptide | |
| JP2008521426A5 (enExample) | ||
| CN104292331B (zh) | 人源抗人α干扰素抗体及其应用 | |
| JP2009524428A5 (enExample) | ||
| AU2021312238A1 (en) | Methods and compositions for treatment and prevention of coronavirus infection | |
| JP7140403B2 (ja) | Ｌｉｇｈｔに結合する抗原結合分子 | |
| CN118994380A (zh) | 抗新型冠状病毒抗体及其应用 | |
| JP2017536821A5 (enExample) | ||
| CA3180251A1 (en) | Cytokine conjugates | |
| WO2016112497A1 (zh) | 人源抗人α干扰素抗体及其应用 |